HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers

NCT04336748 | Withdrawn Phase 3

• 1 other identifier: HCQ prophylaxis for COVID19
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Background: Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo controlled, study. including 440 participants who will be randomised to 2 treatment arms: hydroxychloroquine or placebo. Outcome variables: symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR, viral load during SARS-CoV-2 infection, seroconversion during the study period, incidence of any acute respiratory infection, days of sick leave. Statistical considerations: No trials have been published investigating the efficacy of HCQ as primary prophylaxis of SARS-CoV-2 infection in health care workers. Thus, sample size calculations in the proposed trial are based on the investigators' best estimates for several parameters. In accordance to the effect of oseltamivir against symptomatic influenza, we assumed an approximate effectiveness of approximately 60% (HR of 0.4) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464969/) as realistic. As a prophylactic intervention with HCQ, which may have side effects and for which supply shortage can be expected, was judged justifiable only if its effectiveness is high, we based our sample size consideration on a HR of 0.3. To estimate the probability of an event in both the experimental and the control group, very little data is available. In a Dutch point-prevalence study 0-10% of health-care workers were infected depending on the healthcare institution, depending on the hospital. This point-prevalence study was performed between 6 and 9 March, when the reported number of cases in the Netherlands was 33 and 77, respectively, according to the RIVM (https://www.rivm.nl/nieuws/resultaat-steekproef-4-ziekenhuismedewerkers-heeft-coronavirus). Additionally, in an a report published in the Lancet, 20% of responding healthcare workers in Italy were found to be infected with SARS-CoV2 within less than one month (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30627-9/fulltext). Several media reports indicate that this proportion is similar across various healthcare institutions and countries (https://www.nytimes.com/2020/03/24/world/europe/coronavirus-europe-covid-19.html) and (https://www.aljazeera.com/news/2020/03/spain-tightens-restrictions-week-lockdown-begins-200330191539568.html). As the proposed study will be performed in a high-risk setting, we assumed an event (i.e. PCR positivity) probability of 10% in the control group and 3% in the experimental arm after the maximum study period. In summary, a sample size of 210 participants per arm is necessary to detect a HR of 0.3 with a power of 80.3% with an alpha-error of 0.05. To account for drop-outs and asymptomatic, undetected infection at inclusion or past infection with existing immunity, an additional 10 participants will randomized per treatment arm. The overall study population is therefore 440 participants. Statistical analysis will be based on two populations: A Modified Intention to Treat population excluding those who withdrew consent after randomization and those with a positive serology at baseline. And a per protocol population including all randomized subjects who completed at least 3 out of 4 follow-up visits and took at least 80% of all doses of study medication.

Conditions

Sars-CoV2; Infection Viral; Healthcare Worker; Prophylaxis

Outcome Measures

Primary Outcomes (1)

• Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR

  4 weeks

Secondary Outcomes (4)

• Viral load during SARS-CoV-2 infection

  4 weeks

• Seroconversion during the study period

  4 weeks

• Incidence of any acute respiratory infection

  4 weeks

• Days of sick leave

  4 weeks

Study Arms (2)

Hydroxychloroquine

ACTIVE COMPARATOR

200mg once daily

Drug: Hydroxychloroquine

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Hydroxychloroquine DRUG

low dose (200mg) Hydroxychloroquine once daily for 4 weeks

Hydroxychloroquine

Placebo DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Health-care worker with frequent contact with confirmed COVID-19 patients
• No active or past infection with SARS-CoV-2
• years of age or older
• No allergy or contraindication to hydroxychloroquine
• written informed consent

You may not qualify if:

• Age of less than 18 years
• Pregnancy or lactation
• unwillingness to use effective contraception during the participation in the trial
• Use of concomitant medication that prolongs the QT interval
• Allergy or contraindication to hydroxychloroquine
• Retinopathy or maculopathy
• Neuromuscular diseases (i.e Myasthenia gravis, Parkinson's disease)
• G6PD Deficiency

Sponsors & Collaborators

• Medical University of Vienna: lead

MeSH Terms

Conditions

Virus Diseases

Interventions

Hydroxychloroquine

Condition Hierarchy (Ancestors)

Infections

Intervention Hierarchy (Ancestors)

Chloroquine; Aminoquinolines; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Priv. Doz. Dr.

Study Record Dates

• First Submitted: April 4, 2020
• First Posted: April 7, 2020
• Study Start: April 1, 2020
• Primary Completion: July 1, 2020
• Study Completion: August 1, 2020
• Last Updated: April 12, 2022

Record last verified: 2022-04